ACR-6840
Undisclosed Solid Tumors
PreclinicalActive
Key Facts
About Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology company leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted therapies matched to patients via predictive OncoSignature tests. Its strategy centers on in-licensing and internally developing small molecule inhibitors, with a lead Phase 2 asset, ACR-368, and a dual-inhibitor clinical candidate, ACR-2316. The company aims to improve therapeutic outcomes by directly profiling the functional protein drivers of cancer, a paradigm shift from traditional genomics.
View full company profileTherapeutic Areas
Other Undisclosed Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Macrophage-Targeting Agonist Antibody | Bolt Biotherapeutics | Phase 1 |
| IMA204 | Immatics Biotechnologies | Phase 1 |
| TAR002 | TargImmune Therapeutics | Pre-clinical |
| TAR003 | TargImmune Therapeutics | Pre-clinical |
| Proprietary TCR-NK Platform | Zelluna Immunotherapy | Preclinical |
| ERAS-113 | Erasca | Discovery |
| Multiple Programs | Aktis Oncology | Discovery |
| BAT5506 | Compugen | Preclinical |
| Precision DACs | Prelude Therapeutics | Discovery |
| V2ACT Immunotherapy | Genelux | Phase 1 |
| ATOR-4066 | alligator-bioscience-ab | Discovery/Preclinical |
| ADC Program | Lantern Pharma | Discovery/Preclinical |